Trogocytosis in CAR immune cell therapy: a key mechanism of tumor immune escape DOI Creative Commons

Yizhao Chen,

Qianling Xin,

Mengjuan Zhu

et al.

Cell Communication and Signaling, Journal Year: 2024, Volume and Issue: 22(1)

Published: Oct. 28, 2024

Immune cell therapy based on chimeric antigen receptor (CAR) technology platform has been greatly developed. The types of CAR immune have expanded from T cells to innate such as NK and macrophages, the diseases treated hematological malignancies non-tumor fields infectious autoimmune diseases. Among them, CAR-T CAR-NK observed examples rapid remission in approved clinical trials, but efficacy is unstable plagued by tumor resistance. Trogocytosis a special phenomenon intercellular molecular transfer that common system achieved recipient through acquisition internalization donor cell-derived molecules mediates effects. Recently, novel short-term drug resistance mechanism trogocytosis proposed, bidirectional exchange between triggered partially explains long-term relapse after treatment with cells. In this review, we summarize research progress immunotherapy, discuss influencing factors its direct indirect interference emphasize can further release potential therapy.

Language: Английский

CAR-NK cells for gastrointestinal cancer immunotherapy: from bench to bedside DOI Creative Commons
Xingwang Zhu, Jianxin Xue, Haifeng Jiang

et al.

Molecular Cancer, Journal Year: 2024, Volume and Issue: 23(1)

Published: Oct. 23, 2024

Gastrointestinal (GI) cancers represent a significant health burden worldwide. Their incidence continues to increase, and their management remains clinical challenge. Chimeric antigen receptor (CAR) natural killer (NK) cells have emerged as promising alternative CAR-T for immunotherapy of GI cancers. Notably, CAR-NK offer several advantages, including reduced risk graft-versus-host disease, lower cytokine release syndrome, the ability target cancer through both CAR-dependent cytotoxic mechanisms. This review comprehensively discusses development applications in treatment We explored various sources NK cells, CAR design strategies, current state cell therapy cancers, highlighting recent preclinical trials. Additionally, we addressed existing challenges propose potential strategies enhance efficacy safety therapy. Our findings highlight revolutionize pave way future applications.

Language: Английский

Citations

4
CAR-NK Cell Therapy: A Transformative Approach to Overcoming Oncological Challenges DOI Creative Commons
Wangshu Li, Xiuying Wang, Xu Zhang

et al.

Biomolecules, Journal Year: 2024, Volume and Issue: 14(8), P. 1035 - 1035

Published: Aug. 20, 2024

The use of chimeric antigen receptor (CAR) in natural killer (NK) cells for cancer therapy is gaining momentum, marking a significant shift treatment. This review aims to explore the potential CAR-NK cell immunotherapy, providing fresh perspective. It discusses innovative approaches design and engineering, particularly targeting refractory or recurrent cancers. By comparing with traditional therapies, highlights their unique ability tackle tumor heterogeneity immune system suppression. Additionally, it explains how novel cytokines receptors can enhance efficacy, specificity, functionality. underscores advantages cells, including reduced toxicity, lower cost, broader accessibility compared CAR-T along treating both blood cancers solid tumors.

Language: Английский

Citations

3
Chimeric antigen receptor-natural killer (CAR-NK) cell immunotherapy: A bibliometric analysis from 2004 to 2023 DOI Creative Commons
Wangshu Li, Jiuxiang Feng,

Jianan Peng

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2024, Volume and Issue: 20(1)

Published: Oct. 16, 2024

Chimeric antigen receptor-natural killer (CAR-NK) cells represent a breakthrough in cancer immunotherapy, making this highly popular research area. However, comprehensive analyses of field using bibliometric methods are rare. To our knowledge, study has collected highest number publications (1,259) on CAR-NK therapy from January 1, 2004, to December 31, 2023, and utilized CiteSpace VOSviewer analyze regions, institutions, journals, authors, keywords forecast the latest trends research. The United States China, contributing over 60% publications, primary drivers field. Helmholtz Association Harvard University most active with appearing Frontiers Immunology. Winfried S. Wels is prolific author, while EL Liu frequently co-cited author. "Immunotherapy," "T-cells," "Cancer" extensively covered topics Our reveals current trends, identifies potential hotspots, visualizes references through methods, providing valuable guidance for future

Language: Английский

Citations

2
Engineered T cells for Colorectal Cancer DOI

Nurul Ainaa Adilah Rus Bakarurraini,

Ammar Akram Kamarudin, Rahman Jamal

et al.

Immunotherapy, Journal Year: 2024, Volume and Issue: 16(14-15), P. 987 - 998

Published: Aug. 21, 2024

Colorectal cancer (CRC) is a major contributor to global incidence and mortality. Conventional treatments have limitations; hence, innovative approaches are imperative. Recent advancements in research led the development of personalized targeted therapies immunotherapies. Immunotherapy, particular, T cell-based therapies, exhibited be promising enhancing treatment outcomes. This review focuses on landscape engineered cells as potential option for CRC. It highlights approaches, challenges current this field. As understanding molecular mechanisms increases, hold great revolutionizing treatment. To fully explore their safety efficacy improving patient outcomes, further clinical trials necessary.

Language: Английский

Citations

2
Trogocytosis in CAR immune cell therapy: a key mechanism of tumor immune escape DOI Creative Commons

Yizhao Chen,

Qianling Xin,

Mengjuan Zhu

et al.

Cell Communication and Signaling, Journal Year: 2024, Volume and Issue: 22(1)

Published: Oct. 28, 2024

Immune cell therapy based on chimeric antigen receptor (CAR) technology platform has been greatly developed. The types of CAR immune have expanded from T cells to innate such as NK and macrophages, the diseases treated hematological malignancies non-tumor fields infectious autoimmune diseases. Among them, CAR-T CAR-NK observed examples rapid remission in approved clinical trials, but efficacy is unstable plagued by tumor resistance. Trogocytosis a special phenomenon intercellular molecular transfer that common system achieved recipient through acquisition internalization donor cell-derived molecules mediates effects. Recently, novel short-term drug resistance mechanism trogocytosis proposed, bidirectional exchange between triggered partially explains long-term relapse after treatment with cells. In this review, we summarize research progress immunotherapy, discuss influencing factors its direct indirect interference emphasize can further release potential therapy.

Language: Английский

Citations

2